Earnings Releases·Nov 4, 2026, 4:06 PM ET

McKesson — Fiscal 2027 Second Quarter Earnings Summary

Consolidated Q2 revenues rose 8% year-over-year to $111.0 billion, while adjusted earnings per diluted share increased 18% to $11.68; however, year-to-date net income declined 3% to $1,832 million despite a 12% year-to-date rise in adjusted earnings.
The company raised its fiscal 2027 adjusted earnings per share guidance to $45.60–$46.40, reflecting 17%–19% projected growth, driven by strong performance in North American Pharmaceutical and Oncology & Multispecialty segments.
Strategic activity included a definitive agreement to invest $1.4 billion for a 49% minority interest in Option Care Health, the acquisition of Precision Medicine Group, and the extension of the CVS Health distribution partnership through June 2032.
Capital return totaled $3.6 billion in the first six months, comprising $3.4 billion in stock repurchases and $198 million in dividends, while cash and cash equivalents grew to $6.5 billion and long-term debt increased to $8.4 billion.